Does Dr. CARLOS ACEVEDO REGO have financial conflicts of interest?

Dr. CARLOS ACEVEDO REGO (MD) has received a total of $856 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $856 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. CARLOS ACEVEDO REGO?

According to CMS Open Payments data, Dr. CARLOS ACEVEDO REGO received funding from INTUITY MEDICAL ($255), BAYER HEALTHCARE PHARMACEUTICALS ($124), and STEMLINE THERAPEUTICS ($104).

Does Dr. CARLOS ACEVEDO REGO receive research grants or speaking fees?

Dr. CARLOS ACEVEDO REGO has received $856 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. CARLOS ACEVEDO REGO

MDReal-Time Hydrated

Specialty: General Practice

Practice Location: GUAYAMA, PR 00784

NPI Number: 1902824154

LIFETIME INDUSTRY VALUE

$856

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ACEVEDO REGO is a verified General Practice practitioner based in GUAYAMA, PR.

Between 2021 and 2024, Dr. ACEVEDO REGO had an overall industry promotional and research financial footprint of $856 as recorded in the federal CMS Open Payments database.

$856 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ACEVEDO REGO's primary funding source is INTUITY MEDICAL, which accounts for $255 (representing 29.7% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

INTUITY MEDICAL

Rank 1

$255

29.7%

BAYER HEALTHCARE PHARMACEUTICALS

Rank 2

$124

14.4%

STEMLINE THERAPEUTICS

Rank 3

$104

12.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.